Head and Neck Cancer Registry (LORHAN)

N/ACompletedNCT01080313

Eli Lilly and Company26,000 enrolled

Overview

The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient

Study Type

OBSERVATIONAL

Enrollment

26,000

Conditions

Head and Neck Cancer

Interventions

Therapy for head and neck cancerOTHER

radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin * Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy * Written informed consent Exclusion Criteria: * Registry participation does not exclude participation in clinical trials. * Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.

Locations (1)

Mednet Solutions

Minnetonka, Minnesota, United States

Outcomes

Primary Outcomes

Patterns of care for head and neck cancer

Time frame: up to 10 years

Secondary Outcomes

Overall survival by treatment regimen

Time frame: study entry to death from any cause or to end of study

Determine the incidence and severity of major dose-limiting and other important treatment toxicities

Time frame: up to 10 years

Identify supportive care received for managing nutrition, pain, nausea and other complications

Time frame: up to 10 years

tumor control by treatment regimen

Time frame: study entry to progressive disease

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.